The pharmaceutical company has boosted its stake in mRNA drug developer and strategic partner Moderna to 9%, lifting Moderna's overall funding to at least $790m.
Pharmaceutical firm AstraZeneca invested $140m in US-based RNA therapeutics developer and strategic partner Moderna Therapeutics on Wednesday, increasing its stake in the company to 9%.
Moderna is developing what it calls messenger RNA (mRNA) therapeutics, mRNA being responsible for carrying the genetic instructions transcribed from DNA that cells use as a guide to producing proteins that direct the body’s biological functions.
The result will hopefully be in vivo drugs that will produce antibodies, proteins and protein constructs inside cells in…